Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neuroblastoma 3Melanoma 2Uveal Melanoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Ganglioneuroblastoma 1Congenital Abnormalities 1Carcinoma, Renal Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Melphalan 3tebentafusp 1sargramostim 1fotemustine 1aflibercept 1Ranibizumab 1Nivolumab 1Neoadjuvant Therapy 1Melatonin 1MART-1 Antigen 1Ipilimumab 1Eye Enucleation 1Dacarbazine 1Colony-Stimulating Factors 1Chemotherapy, Cancer, Regional Perfusion 1Brachytherapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uveal Melanoma × Colony-Stimulating Factors × Clear all
NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡